INSIGHTS ON DRUG DEVELOPMENT

• Integrated QC As A Development Strategy: Reducing Late-Stage Analytical Risk

  Learn how early QC integration, proactive analytical risk management, and cross-functional collaboration can improve validation readiness, reduce development surprises, strengthen release testing predictability, and help protect critical clinical manufacturing timelines.

• Excipients For Respiratory Delivery Of Biologics

  With only 105 FDA-approved excipients for nasal and inhalation routes, formulating biologics for respiratory delivery demands precise excipient selection across both liquid and solid dosage forms.

• Eliminate Risk From Your Viral Vector Tech Transfers

  Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.

• The Body As A Bioreactor – Delivering The Vision

  Making the body a bioreactor requires precise delivery to selected cells. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.

• Rational Design And Material-sparing Strategies For Enabled Intermediates And Drug Products

  9/9/2026

  A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.

• Navigating The Development Of Dry Powder For Inhalation

  9/9/2026

  A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and encapsulation considerations.

• Efficiently Optimize Your Workflow With Single-Use Chromatography

  11/4/2025

  Explore how low-volume purification can be done more efficiently in GMP settings with a live system demo and customer insights on optimizing workflows with single-use chromatography.

• Improving API Solubility With Mesoporous Silica

  6/5/2025

  Poor solubility of active pharmaceutical ingredients can hinder drug effectiveness. Learn how innovative formulation strategies enhance solubility and bioavailability to improve therapeutic outcomes for challenging drug candidates.

• Scale-Up Of A Transient rAAV Production Process

  11/3/2025

  Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.